Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
With
Procter and Gamble
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
• Symptoms of OAB for at least six months prior to randomization
* ≥ 8 micturitions on average/24 hours
* ≥ 1 urgency episodes on average/24 hours
* with or without UUIE
* Patients dissatisfied with prior oxybutynin ER or tolterodine ER treatment. Patients must have been on either treatment for at least 1 week and up to 12 months preceding this study. It is required that either oxybutynin ER or tolterodine ER was the most recent OAB medication taken.
* Patients without prior darifenacin treatment
You may not be if
• A mean daily urinary volume \>3000 mL or a mean volume voided/micturition of \>300 mL as verified in the micturition diary for two consecutive days prior to Baseline
* Males with post-void residual (PVR) urinary volume \>200 mL at Baseline
* Clinically predominant and bothersome stress urinary incontinence, as determined by the investigator
* Urinary retention or clinically significant bladder outlet obstruction as determined by the investigator
Clareo Health | Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
